FDA broadens afatinib indication to previously untreated, metastatic NSCLC with other non-resistant EGFR mutations

The Food and Drug Administration granted approval to afatinib for a broadened indication in first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have non-resistant epidermal growth factor receptor (EGFR)...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2n5T9rd
via IFTTT